Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP‐1R activation
- 27 February 2014
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (5) , 1114-1128
Abstract
The incidence of type 2 diabetes in developed countries is increasing yearly with a significant negative impact on patient quality of life and an enormous burden on the healthcare system. Current biguanide and thiazolidinedione treatments for type 2 diabetes have a number of clinical limitations, the most serious long‐term limitation being the eventual need for insulin replacement therapy (Table 1). Since 2007, drugs targeting the glucagon‐like peptide‐1 (GLP‐1) receptor have been marketed for the treatment of type 2 diabetes. These drugs have enjoyed a great deal of success even though our underlying understanding of the mechanisms for their pleiotropic effects remain poorly characterized even while major pharmaceutical companies actively pursue small molecule alternatives. Coupling of the GLP‐1 receptor to more than one signalling pathway (pleiotropic signalling) can result in ligand‐dependent signalling bias and for a peptide receptor such as the GLP‐1 receptor this can be exaggerated with the use of small molecule agonists. Better consideration of receptor signalling pleiotropy will be necessary for future drug development. This is particularly important given the recent failure of taspoglutide, the report of increased risk of pancreatitis associated with GLP‐1 mimetics and the observed clinical differences between liraglutide, exenatide and the newly developed long‐acting exenatide long acting release, albiglutide and dulaglutide.Linked Articles: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue‐5Keywords
This publication has 213 references indexed in Scilit:
- Snapin Mediates Incretin Action and Augments Glucose-Dependent Insulin SecretionCell Metabolism, 2011
- Glucagon-like Peptide-1 Increases β-Cell Glucose Competence and Proliferation by Translational Induction of Insulin-like Growth Factor-1 Receptor ExpressionJournal of Biological Chemistry, 2010
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trialThe Lancet, 2010
- GLP-1 Mediates Antiapoptotic Effect by Phosphorylating Bad through a β-Arrestin 1-mediated ERK1/2 Activation in Pancreatic β-CellsJournal of Biological Chemistry, 2010
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cellsProceedings of the National Academy of Sciences, 2008
- Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMPProceedings of the National Academy of Sciences, 2007
- β cell-specific deficiency of the stimulatory G protein α-subunit G s α leads to reduced β cell mass and insulin-deficient diabetesProceedings of the National Academy of Sciences, 2007
- Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric bandingSurgery for Obesity and Related Diseases, 2007